San Diego (ots/PRNewswire) – Neomorph, Inc. today announced that it has entered into a collaboration and licensing agreement with global healthcare company Novo Nordisk to discover, develop and commercialize molecular adhesive degraders. Neomorph, a biotechnology company solving critical human health problems by discovering novel therapeutics against “untreatable” targets, was founded in 2020 and is backed by Deerfield Management Company.
- Collaboration leverages Neomorph’s leading molecular adhesive discovery platform and Novo Nordisk’s extensive expertise in cardiometabolic and rare diseases
- Potential total deal value of $1.46 billion across multiple targets
“We are excited to partner with Novo Nordisk, a world-class healthcare company in diabetes, obesity and rare blood diseases,” said Phil Chamberlain, DPhil, co-founder, president and CEO of Neomorph. “By combining the company’s proprietary discovery platform of Neomorph adhesives with Novo Nordisk’s extensive experience in cardiometabolic and rare diseases, we are well positioned to develop transformative treatments in these areas. This collaboration will enable the expansion of our platform into new therapeutic areas and complement our ongoing efforts in oncology.”
Under the terms of the agreement, Neomorph will receive an upfront payment and short-term milestone payments as well as funding for research and development. Neomorph is also eligible to receive future clinical, commercial and sales milestone payments, bringing the total potential value of the multi-target deal to $1.46 billion, plus tiered royalties. Neomorph will lead the discovery and preclinical activities against selected targets, with Novo Nordisk having the right to exclusively pursue further clinical development and commercialization of the compounds.
“Novo Nordisk is expanding its drug discovery efforts, leveraging a range of novel technology platforms to discover and develop new treatment solutions for people with serious chronic diseases. We are excited about this research collaboration and look forward to scientific work on the novel class of molecular adhesive degraders that Neomorph is pioneering,” said Brian Vandahl, senior vice president of global research technologies at Novo Nordisk.
Information about NeomorphNeomorph
is a biotechnology company solving critical human health problems through the discovery and development of innovative new medicines against “incurable” targets. Neomorph was founded in 2020 and is backed by Deerfield Management Company.
Neomorph’s team includes industry-leading experts in protein degradation and molecular adhesives with groundbreaking discoveries in the field. The Neomorph team is committed to advancing the science and technology of molecular glue drug discovery while advancing a number of projects through clinical development.
Neomorph’s headquarters are located in San Diego, California. For more information, see www.neomorph.com and follow us on LinkedIn.
Questions & Contact:
Contact:
Investorenkontakt: inquiries@neomorph.com
Media contact: media@neomorph.com
Logo – https://mma.prnewswire.com/media/2341384/Neomorph_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/neomorph-knows-multi-target-collaboration-with-novo-nordisk-an-um-neue-molecular-glue-degraders-for-cardiometabolic-and- rare-diseases-to-discover-302070217.html